NCT01697631View on ClinicalTrials.gov

Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

July 22, 2002

Primary Completion Date

April 24, 2003

Study Completion Date

April 24, 2003

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals

DRUG

insulin aspart

Administrated subcutaneously (s.c., under the skin) before lunch

Trial Locations (12)

15-276

Novo Nordisk Investigational Site, Bialystok

41-902

Novo Nordisk Investigational Site, Bytom

57-230

Novo Nordisk Investigational Site, Kamieniec Ząbkowicki

40-053

Novo Nordisk Investigational Site, Katowice

31-261

Novo Nordisk Investigational Site, Krakow

48-300

Novo Nordisk Investigational Site, Nysa

05-400

Novo Nordisk Investigational Site, Otwock

26-600

Novo Nordisk Investigational Site, Radom

41-700

Novo Nordisk Investigational Site, Ruda Śląska

41-200

Novo Nordisk Investigational Site, Sosnowiec

01-877

Novo Nordisk Investigational Site, Warsaw

50-306

Novo Nordisk Investigational Site, Wroclaw

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY